JPRN-jRCT2031210284招募中未知
Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case surveillance)
Contact for Clinical Trial Information0 个研究点目标入组 120 人开始时间: 2021年8月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All participants in Japan who received teduglutide will be enrolled in this post marketing surveillance.
排除标准
- 未提供
研究者
相似试验
招募中
不适用
A STUDY OF DRUG UTILIZATION PATTERN IN THE TREATMENT OF SEVERE INFECTION IN A HOSPITACTRI/2015/02/005492KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES100
尚未招募
Unknown
Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)Prurigo nodularisJPRN-UMIN000051970Sanofi K.K.100
已完成
不适用
Dupixent Special Drug Use Investigation for long term useAtopic dermatitisJPRN-UMIN000032807Sanofi K.K.1,000
尚未招募
Unknown
Dupixent Special Drug Use Investigation for long term use (Pediatric Atopic Dermatitis)Atopic DermatitisJPRN-UMIN000052375Sanofi K.K.70
进行中（未招募）
不适用
Protocol Number; CAIN457L1401JPRN-jRCT2031210589Toshiya Sugimoto35